ESE Clinical Guideline: Treatment of chronic hypoparathyroidism in adults

Hypoparathyroidism (HypoPT) is a rare (orphan) endocrine disease characterised by low calcium and inappropriately low (insufficient) circulating parathyroid hormone levels, most often in adults secondary to thyroid surgery. HypoPT is a major endocrine deficiency disease not treated by hormone replacement. Very little evidence is available on how best to treat HypoPT. Clinical trials on how to optimise therapy are essentially non-existent. Owing to this remarkable lack of data, it is not possible to formulate recommendations based on strict evidence.

The Guideline reported here was developed and solely sponsored by the European Society of Endocrinology, supported by CBO (Dutch Institute for Health Care Improvement) and based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles as a methodological base. The purpose of this guideline is to provide clinicians with guidance on the treatment and monitoring of chronic HypoPT in adults who do not have end-stage renal disease.

Read the full guideline titled ’ European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults’ by Bollerslev et al, in European Journal of Endocrinology 173 G1-G20.

DOI: 10.1530/EJE-15-0628